Abbott Laboratories (ABT) said Tuesday that the U.S. Food and Drug Administration approved the Omnilink Elite Vascular Balloon-Expandable Stent System for the treatment of iliac artery disease, a form of peripheral artery disease that affects the lower extremities.
The FDA approval is supported by positive clinical data from the MOBILITY (Omnilink Elite or Absolute Pro Stent Used in the Iliac Artery) study, which demonstrated that Omnilink Elite is safe and effective.
Omnilink Elite is the latest addition to Abbott's U.S. portfolio of endovascular products for the treatment of peripheral artery disease.
For comments and feedback: editorial@rttnews.com